Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01654120 · ClinicalTrials.gov registry record · Phase 4

Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics

A Phase 4 study of Diabetes Mellitus Type II, sponsored by Mountain Diabetes and Endocrine Center.

Completed
Registry status
Phase 4
Development phase
37
Enrollment target
1
Study location

NCT01654120 is a Phase 4 study of Diabetes Mellitus Type II that has completed, run by Mountain Diabetes and Endocrine Center. The registered enrollment target is 37 participants, below the 235-participant average among 7 other Diabetes Mellitus Type II trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01654120, a Phase 4 study of Diabetes Mellitus Type II, has completed, sponsored by Mountain Diabetes and Endocrine Center.

COMPLETED
Registry status
Phase 4
Development phase
37 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the effect of adding liraglutide to high dose insulin therapy compared to high dose insulin therapy alone in patients with insulin-treated Type 2 diabetes with insulin requirements of \> 100 units of insulin per day.

Conditions Studied

Interventions

  • DRUG Liraglutide
  • DRUG Insulin

Study Locations (1)

North Carolina

  • Mountain Diabetes and Endocrine Center - Asheville

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2011-12
Est. Completion 2013-11
Phase Phase 4

What the Registry Record Tells You About NCT01654120

The ClinicalTrials.gov registry entry for NCT01654120 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 235-participant average among 7 other Diabetes Mellitus Type II trials with a reported enrollment target (84% lower). The listed sponsor is Mountain Diabetes and Endocrine Center, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus Type II appearing as the primary indexed condition, and to 2 interventions - of which Liraglutide is the first listed.

NCT01654120 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT01654120 about?

NCT01654120 is a clinical study titled "Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics". The purpose of this study is to determine the effect of adding liraglutide to high dose insulin therapy compared to high dose insulin therapy alone in patients with insulin-treated Type 2 diabetes with insulin requirements of \> 100 units of insulin per day.

What is the current status of trial NCT01654120?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2011-12. Estimated completion is 2013-11.

What conditions does trial NCT01654120 study?

This clinical trial studies the following conditions: Diabetes Mellitus Type II.

What interventions are being tested in trial NCT01654120?

The interventions under investigation include: Liraglutide (DRUG), Insulin (DRUG).

Who is sponsoring clinical trial NCT01654120?

This trial is sponsored by Mountain Diabetes and Endocrine Center, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01654120 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus Type II

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.